SMAD4 and hereditary hemorrhagic telangiectasia: In addition to these, recent studies have reported a potential pathogenic role of mutations in the RASA1 gene and suggest that their inclusion in molecular screening for HHT patients without ENG, ACVRL1, or SMAD4 mutations could aid in a correct diagnosis [8].